Lipigon Pharmaceuticals (LPGO) Q4 2025 earnings summary

Executive summary

• Topline data from the phase II study of Lipisense® showed good safety but no clinically relevant reduction in triglycerides or remnant cholesterol; a trend toward improved insulin resistance was observed.

• A strategic review was initiated, and cost-saving measures were implemented to reduce the cost base by about 65%.

• The company is evaluating strategic alternatives, including partnerships and new indications, due to limited liquidity and the need for additional financing.

Financial highlights

• Net sales for Jan–Dec 2025 were 0 tkr, down from 10,287 tkr in the previous year.

• Operating loss for Jan–Dec 2025 was -32,218 tkr, compared to -25,576 tkr year-over-year.

• Cash and cash equivalents at year-end were 10,214 tkr, down from 11,775 tkr.

• Equity at year-end was 7,912 tkr, with an equity per share of 0.01 kr.

• Soliditet (equity ratio) improved to 68.9% from 52.4% year-over-year.

Outlook and guidance

• The company lacks sufficient working capital for the next twelve months and requires new financing to continue operations.

• If the ongoing strategic review does not yield satisfactory results, bankruptcy may be considered.